Ineffectiveness of the presence of H-ras/p53 combination of mutations in squamous cell carcinoma cells to induce a conversion of a nontumorigenic to a tumorigenic phenotype

Cell Biology and Toxicology

Volumn 13, Issue 6, 1997, Pages 419-434

  Lee, H ^a   Li, D ^a   Prior, T ^a   Casto, B C ^a   Weghorst, C M ^a   Shuler, C F ^b   Milo, G E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

H ras; Human tumors; Mutations; p53; Tumorigenicity

Indexed keywords

MESYLIC ACID METHYL ESTER; METHYLNITRONITROSOGUANIDINE; PROTEIN P53;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; HUMAN; MALE; MOUSE; MUTATION; NONHUMAN; ONCOGENE H RAS; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANIMALS; AUTORADIOGRAPHY; BLOTTING, NORTHERN; CARCINOMA, SQUAMOUS CELL; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; MALE; METHYL METHANESULFONATE; METHYLNITRONITROSOGUANIDINE; MICE; MICE, NUDE; MUTATION; PHENOTYPE; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0030766184     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007419810705     Document Type: Article

References (79)

1. Addison C, Jenkins JR, Sturzbecher HW. The p53 nuclear localization signal is structurally linked to a p34cdc2 kinase motif. Oncogene. 1990;5:423-6.
2. Baker SJ, Preisinger AC, Jessup JM et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990a;50:7717-22.
3. Baker SJ, Markowitz S, Fearon DR, Wilson JKU, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990b;249:912-5.
4. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-9. [Published erratum appears in Cancer Res. 1990;50:1352].
5. Boukamp P, Peter W, Pascheberg U et al. Step-wise progression in human skin carcinogenesis in vitro involves mutational inactivation of p53, rasH oncogene activation and additional chromosome loss. Oncogene. 1995;11:961-9.
6. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res. 1990;50:2840-7.
7. Budlowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet. 1991;48:137-44.
8. Cabrero CA, Diez EV, Carracedo A, Alemany J. Allele frequency distribution of four PCR-amplified loci in the Spanish population. Forens Sci Int. 1995;71:153-64.
9. Cajot J-F, Anderson MJ, Lehman TA, Shapiro H, Briggs AA, Stanbridge EJ. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein. Cancer Res. 1992;52:6956-60.
10. Cariello NF, Cui L, Beroud C, Soussi T. Database and software for the analysis of mutations in the human p53 gene. Cancer Res. 1994;54:4454-60.
11. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer. 1992;4:1-15.
12. Chang SE, Bhatia P, Johnson NW et al. ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer. 1991;48:409-12.
13. Chen J, Milo GE, Shuler CF, Schuller DE. Xenograft growth and histodifferentiation of squamous cell carcinomas of the pharynx and larynx. Oral Surg Oral Med Surg Oral Pathol Oral Radiol Endod. 1996;81:197-202.
14. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265:346-355.
15. Chumakov PM. EMBL data library, Accession Number X54156. 1990.
16. Clore GM, Omichinski JG, Sakaguchi K et al. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science. 1994;265:386-91.
17. Diller L, Kassel J, Nelson CE et al. p53 functions as a cell cycle control protein in osteosarcoma. Mol Cell Biol. 1990;10:5772-81.
18. Dittmer D, Pati S, Zambetti G et al. Gain of function mutations in p53. Nature Genet. 1993;4:42-6.
19. Eliyahu D, Raz A, Gruss P, Givol D, Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 1984;312:646-9.
20. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras. Science. 1993;260:1524-7.
21. Gerwin BI, Spillare E, Forrester K et al. Mutant p53 can induce tumorigenic conversion of human bronchial cells and reduce their responsiveness to a negative growth factor, transforming growth factor β-1. Proc Natl Acad Sci USA. 1992;89:2759-63.
22. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-78.
23. Gyllensten UB, Erlich HA. Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci USA. 1988;85:7652-6.
24. Hall A. A biochemical function for ras - at last. Science. 1994;264:1413-4.
25. Hammond HA, Li Jin YZ, Caskey CT, Chakraborty R. Evaluation of 13 short tandem repeat loci for use in personal identification applications. Am J Hum Genet. 1994;55:175-89.
26. Higuchi R. Simple and rapid preparation of samples for PCR. In: Erlich HA, ed. PCR technology - Principles and applications for DNA amplification. New York: Stockton Press; 1989:31-8.
27. Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol. 1989;63:739-46.
28. Hinds PW, Finlay CA, Quartin RS et al. Mutant p53 cDNAs from human colorectal carcinomas can cooperate with ras in transformation of primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1990;1:571-80.
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
30. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335:675-9.
31. Jenkins JR, Rudge K, Currie GA. Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53. Nature. 1984;312:651-4.
32. Kikuchi-Yanoshita R, Konishi M, Ito S et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 1992;52:3965-71.
33. Kikuchi-Yanoshita R, Tanaka K, Muraoke M et al. Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene. Oncogene. 1995;11:1339-45.
34. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77-9.
35. Lehman TA, Bennett WP, Metcalf RA et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991;51:4090-6.
36. Li D, Noyes I, Shuler CF, Milo GE. Cloning and sequencing of CATR1.3, a human gene associated with tumorigenic conversion. Proc Natl Acad Sci USA. 1995;92:6409-13.
37. Li D, Hua Y, Chen J, Casto BC, Theil KS, Milo GE. Malignant conversion of human cells by antisense cDNA to a putative tumor suppressor gene. Carcinogenesis. 1996;17:1751-5.
38. Mercer WF, Shields MT, Amin M et al. Antiproliferative effects of wild-type human p53. J Cell Biochem. 1990;14C:285.
39. Milo GE, Lee H. Molecular control of expression of plasticity of tumorigenic/metastatic phenotypes. In: Rhim JS, Dritschilo A, eds. Neoplastic transformation in human cell culture. Totowa, NJ: Humana Press; 1991:223-32.
40. Milo GE, Yohn J, Schuller D, Noyes I, Lehman T. Comparative stages of expression of human squamous carcinoma cells and carcinogen transformed keratinocytes. J Invest Dermatol. 1989;92:848-53.
41. Milo GE, Shuler C, Kurian P et al. Nontumorigenic squamous cell carcinoma line converted to tumorigenicity with methyl methanesulfonate without activation of HRAS or MYC. Proc Natl Acad Sci USA. 1990;87:1268-72.
42. Milo GE, Shuler C, Stoner G, Chen J-C. Conversion of premalignant human cells to tumorigenic cells by methyl methanesulfonate and methylnitrosoguanidine. Cell Biol Toxicol. 1992;8:193-205.
43. Milo GE, Li D, Casto BC et al. Malignant conversion of chemically transformed normal human cells. Proc Natl Acad Sci USA. 1996;93:5229-34.
44. Mitsudomi T, Steinberg SM, Nau MM et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992;7:171-80.
45. Mount SM. A catalogue of splice junction sequences. Nucleic Acids Res. 1982;10:459-72.
46. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-8.
47. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991;338:1356-9.
48. Parada LF, Hartmut L, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 1984;312:649-51.
49. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993;7:2556-64.
50. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ, Stanbridge EJ. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci USA. 1996;93:6665-70.
51. Ponchel F, Puisieux A, Tabone E et al. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor β1-mediated apoptosis. Cancer Res. 1994;54:2064-8.
52. Quartin RS, Levine AJ. A comparison of the properties of human p53 mutant alleles. In: Yang SS, Warner HR, eds. The underlying molecular cellular, and immunological factors in cancer and aging. New York: Plenum Press; 1993:55-65.
53. Rheinwald JG, Beckett MA. Tumorigenic keratinocytes lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res. 1981;41:1657-63.
54. Ridgway PJ, Hale TK, Braithwaite AW. p53 confers a selective advantage on transfected HeLa cells. Oncogene. 1993;8:1069-74.
55. Rovinski B, Benchimol S. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene. 1988;2:445-52.
56. Rumsby G, Carter RL, Gusterson BA. Low incidence of ras oncogene activation in human squamous cell carcinomas. Br J Cancer. 1990;61:365-8.
57. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene. 1992;7:927-33.
58. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Press; 1989.
59. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463-7.
60. Saranath D, Chang SE, Bhoite LT et al. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer. 1991;63:573-8.
61. Shuler C, Kurian P, French BT et al. Noncorrelative c-myc and ras oncogene expression in squamous cell carcinoma cells with tumorigenic potential. Teratogen Carcinogen Mutagen. 1990;10:53-65.
62. Shuler CF, Milo GE. Morphologic and molecular characterizations of plastic tumor cell phenotypes. In: Milo GE, Casto BC, Shuler CF, eds. Transformation of human epithelial cells: molecular and oncogenetic mechanisms. Boca Raton: CRC Press; 1992:211-34.
63. Slingerland JM, Benchimol S. Transforming activity of mutant human p53 alleles. J Cell Physiol. 1991;148:391-5.
64. Slingerland JM, Minden MD, Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia. Blood. 1991;77:1500-7.
65. Slingerland JM, Jenkins JR, Benchimol S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. EMBO J. 1993;12:1029-37.
66. Soussi T, de Fromentel CC, Mechali M, May P, Kress M. Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene. 1987;1:71-8.
67. Sun Y, Nakamura K, Wendel E, Colburn N. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA. 1993;90:2827-31.
68. Tadokoro K, Ueda M, Ohshima T et al. Activation of oncogenes in human oral cancer cells: a novel codon 13 mutation of c-H-ras-1 and concurrent amplifications of c-erbB-1 and c-myc. Oncogene. 1989;4:499-505.
69. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-6.
70. Williams AC, Browne SJ, Yeudal WA et al. Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma. Oncogene. 1993;8:3063-72.
71. Williams AC, Harper SJ, Paraskeva C. Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. Cancer Res. 1990;50:4724-30.
72. Williams AC, Browne SJ, Manning AM, Daffada P,Collard TJ, Paraskeva C. Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-β1. Oncogene. 1994;9:1479-85.
73. Wolf D, Harris N, Rotter V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell. 1984;38:119-26.
74. Wong Z, Wilson V, Patel I, Povey S, Jeffreys AJ. Characterization of a panel of highly variable minisatellites cloned from human DNA. Ann Human Genet. 1987;51:269-88.
75. Wyllie FS, Lemoine NR, Barton CM, Dawson T, Bond J, Wynford-Thomas D. Direct growth stimulation of normal human epithelial cells by mutant p53. Mol Carcinogen. 1993;7:83-8.
76. Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res. 1991;51:6506-9.
77. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 1992;52:4196-9.
78. Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M, Sager R. Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res. 1988;48:7041-7.
79. Zambetti GF, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 1993;7:885.